Storia in 5 fonti

The 'Best-Case Scenario' That Shot Arrowhead Stock Sky-High

Arrowhead Pharmaceuticals' triglycerides-buster hit the "best-case scenario" in two studies Wednesday.

Raccontata da

Confronto fonti

5 prospettive sulla stessa storia

AI · summaries

investors.comStai leggendo1 mese fa

The 'Best-Case Scenario' That Shot Arrowhead Stock Sky-High

Arrowhead Pharmaceuticals' triglycerides-buster hit the "best-case scenario" in two studies Wednesday.

originale

Timeline cronologica

mercoledì 22 luglio 2026·biopharmadive.com
Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug
To analysts, the drug’s apparent safety and effects on both triglyceride levels and pancreatitis cases should make it competitive with a rival Ionis therapy.
mercoledì 22 luglio 2026·investors.com
The 'Best-Case Scenario' That Shot Arrowhead Stock Sky-High
Arrowhead Pharmaceuticals' triglycerides-buster hit the "best-case scenario" in two studies Wednesday.

benzinga.com

1 mese fa

Arrowhead Drug Shows Strong Efficacy In Cutting Blood Fat - Arrowhead Pharma (NASDAQ:ARWR)

The latest Arrowhead drug study showed positive results, with significant triglyceride and pancreatitis reductions.

Leggi questa versione → originale

biopharmadive.com1 mese fa

Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug

To analysts, the drug’s apparent safety and effects on both triglyceride levels and pancreatitis cases should make it competitive with a rival Ionis therapy.

Leggi questa versione → originale

endpoints.news1 mese fa

Arrowhead’s gene silencer competitive with Ionis’ in triglyceride disease

Arrowhead's Redemplo cut triglycerides 79%-81% in two Phase 3 trials for sHTG, boosting the company's shares by about 25%.

Leggi questa versione → originale

fiercepharma.com1 mese fa

Look out Ionis, here comes Arrowhead with promising hypertriglyceridemia data

Less than a month after Ionis Pharmaceuticals scored an FDA expansion for Tryngolza to become t | Less than a month after Ionis scored an FDA expansion for Tryngolza to become the first drug to specifically treat severe…

Leggi questa versione → originale

mercoledì 22 luglio 2026·

fiercepharma.com

Look out Ionis, here comes Arrowhead with promising hypertriglyceridemia data

Less than a month after Ionis Pharmaceuticals scored an FDA expansion for Tryngolza to become t | Less than a month after Ionis scored an FDA expansion for Tryngolza to become the…

mercoledì 22 luglio 2026·

endpoints.news

Arrowhead’s gene silencer competitive with Ionis’ in triglyceride disease

Arrowhead's Redemplo cut triglycerides 79%-81% in two Phase 3 trials for sHTG, boosting the company's shares by about 25%.

mercoledì 22 luglio 2026·

benzinga.com

Arrowhead Drug Shows Strong Efficacy In Cutting Blood Fat - Arrowhead Pharma (NASDAQ:ARWR)

The latest Arrowhead drug study showed positive results, with significant triglyceride and pancreatitis reductions.